IL6 and prostate cancer: The anti-IL6 antibody siltuximab (CNTO 328) was shown to inhibit the proliferation in vitro and in vivo of prostate tumors and delayed progression to castration resistance in experimental models; however, at clinical level, this antibody was not successful in monotherapy in phase I/II studies in prostate cancer patients [602].